41results about How to "Low therapeutic dose" patented technology

The invention relates to a astragaloside liposome and method for preparing same, wherein the liposome is prepared from astragaloside, phosphatide and lipophilic additives, the weight ratio of phosphatide and astragaloside is 0.5:1-100:1, the weight ratio of phosphatide and lipophilic additives is 1:1-50:1. The liposome can be used for preparing powdered inhalant, aerosols, sprays and oral mucosa doses.

The invention discloses a preparation method of small unilamellar vesicle liposome of ivermectin, and relates to a preparation method of ivermectin liposome, which solves the problems that the existing ivermectin preparation has short effective date, and needs to deliver drug repeatedly and the sustained release macro-pill of the ivermectin has high toxicity. The method comprises the following steps of: adding raw ivermectin powder in organic solution of soya bean lecithin and cholesterol, then carrying out pressure reduction, rotation and evaporation to the obtained injectable suspension tilla layer of thin film is formed at the inner wall of a reactor, then dissolving the thin film in PBS solution, adding glass beads into a rotary-type oscillator, shaking to wash the film for 1 hour, then standing for 1 hour, and carrying out ultrasonic oscillation so as to obtain the small unilamellar vesicle liposome of ivermectin. The liposome obtained by the preparation method has similar structure as a biofilm, can be biodegraded in the organism, does not generate toxic substances, and can be slowly and continuously released as embedded drug in a storage mode, thus being capable of prolonging effective horizontal period of the drug and reducing drug delivery frequency; and the packet rate of the small unilamellar vesicle liposome of ivermectin is 89.5%.

The present invention provides a modified release dosage form of tacrolimus that releases two or more amount of tacrolimus upon oral administration, the first amount of tacrolimus releases from the immediate release dosage unit substantially immediately within 0-2 hours followed by a time interval ranging from about 1-10 hours during which substantially no amount of tacrolimus is released from thedosage form, after which a second amount of tacrolimus is released wherein said second amount is released from the delayed release dosage unit either immediately e.g. within 0-2 hours or over a period of time ranging from about 2-12 hours from its initial release from the delayed release dosage unit. The dosage form may further comprise additional amount of tacrolimus to provide additional pulseof tacrolimus. The dosage forms of tacrolimus exhibit improved bioavailability and reduced flux or fluctuation over existing composition of tacrolimus. A method of preparing the dosage forms is also described.

Nanoparticulate compositions containing corticosteroids and leukotriene receptor antagonists are described. The composition is used for prevention and long-term treatment of asthma in adults and children, and for relieving symptoms of allergic conjunctivitis and seasonal allergic rhinitis in adults and children. Combining a leukotriene receptor antagonist in the particle size range of less than 2000nm with a corticosteroid in one formulation resulted in increased potency. Additionally, patient compliance is enhanced since only one dosage form is required. Furthermore, topical administration of leukotriene receptor antagonists results in lower hepatotoxicity, since the liver will be exposed to a smaller amount of drug than would be the case after oral administration. The pharmaceutical compositions of the present invention may be formulated for inhalation, nasal or ophthalmic use.

A pharmaceutical composition for treating allergic rhinitis comprises one or a plurality of kinds from methylprednisolone taken as active ingredient or pharmaceutically acceptable salt thereof or esterified matters thereof, and a pharmaceutical composition consisting of one or a plurality of inactive ingredients applicable to local action inside nasal cavity.

In the present invention, a new combination is disclosed comprising (i) 5-aminosalicylic acid (5-ASA) or a derivative thereof, or a pharmacologically acceptable salt thereof, and (ii) a group D vitamin, a derivative thereof, a metabolite or analogue, for use in the prevention and / or treatment of colorectal cancer (CRC). A further aspect of the invention is directed to pharmaceutical compositions comprising said combination together with at least one physiologically acceptable excipient and the use thereof in the prevention and / or in the treatment of the colorectal cancer.

The invention discloses a lymph purification therapeutic apparatus provided with a thoracic duct lymph drainage tube. An end of the thoracic duct lymph drainage tube includes three branches that are connected with a drainage tube pressure sensitive cuff, a drive pump and a lymph purifier outlet; the driving pump is connected with a suction jar that is connected with a lymph purifier inlet; the lymph purifier is connected with a displacement liquid feeder. This apparatus drains all lymph out from the intestinal system, thus avoiding blood entry; low disturbance is caused to the internal environment; the anticoagulation problem is weakened, and the risk of bleeding and clotting is greatly reduced; a therapeutic dose is low; a treatment period is shortened; the influence of bedside blood purification therapy on drug removal can be reduced, and high efficient drug concentration in blood is maintained, thus improving therapeutic effect of drugs such as antibiotics, reducing dosage of the antibiotics, reducing drug resistance and lowering drug therapy related costs.

The invention discloses application of a traditional Chinese medicine composition to preparation of a drug for treating allergic conjunctivitis, relating to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from Chinese herbal medicines such as honeysuckle, semen cassiae, semen plantaginis, scutellaria baicalensis, mint, equisetum hyemale, climbing groundsel herbs and liquorice. The traditional Chinese medicine composition disclosed by the invention is high in effect taking speed, short in treatment course and high in cure rate and can be popularized and applied on the aspect of treating allergic conjunctivitis. The traditional Chinese medicine composition disclosed by the invention can take a synergistic effect and simultaneously take the effects of dispelling wind and evils, clearing away heat and toxic materials as well as dispelling wind and arresting itching.

The invention belongs to the technical field of medicine and relates to the application of 3,5-dinitrophenyl-pyrazolo[3,4-d][1,3]oxazine as a tumor drug resistance reversal agent. Research of the present invention shows that 1-phenyl-6-(3,5-dinitrophenyl)-pyrazolo[3,4-d][1,3]oxazin-4(1H)-ketone can significantly improve The sensitivity of tumor cells to anti-tumor drugs can reverse the drug resistance of tumor cells, and the treatment dose is safe and non-toxic, which has the potential to become a new type of tumor drug resistance reversal agent. Based on the results of this study, the above-mentioned compounds can be used as adjuvant therapy of chemotherapy regimens and co-administered with other anti-tumor drugs, which has good clinical significance.

The invention provides a niobium tungstate compound for resisting hepatitis virus, which has the function of resisting the hepatitis virus and the chemical formula of AmBr (X (NbO2) 3W9O37). nH2O, wherein A is alkali metal ion Li, Na, K or Cs; B is hydrogen cation H+, ammonium ion NH4+ or amino acid cation; X is Si, Ge or P; and m=0-7, r=0-7 and n=0-20. The niobium tungstate compound is taken as active ingredient which is assisted by carrier or auxiliary material that is pharmaceutically acceptable, thus being used for preparing oral preparation or injection medicine applied to treating hepatitis. Compared with the existing medicine which is applied to treating hepatitis clinically, the niobium tungstate compound has the advantages of better liver target, low effective therapeutic dose, higher therapeutic index and lower toxicity, thus being an antiviral compound which has higher efficiency and is safer.

The invention discloses a hydroxyl camptothecin flexible liposome and a preparation method thereof. The method comprises the following steps of: dissolving hydroxyl camptothecin and carrier materials, such as phospholipid, cholesterol and the like, in an organic solvent; forming the mixture into a membrane in water bath through rotary evaporation; and adding buffer solution which contains chitosan into the membrane to form the hydroxyl camptothecin flexible liposome. The hydroxyl camptothecin flexible liposome is relatively lower in toxicity, relatively longer in residence time in a body, high in stability in a solution phase and smalllow in particle size, and the particle size of the liposome is not obviously changed after the liposome is lyophilized.

The invention discloses a medicine composition containing inorganic arsenic compounds and application thereof. The medicine composition comprises inorganic arsenic compounds, scutellarin or scutellarein, is used for preparing medicines for treating cancers, and has a better effect on cancer cell inhibition than that by singly using inorganic arsenic compounds and that by singly using scutellarin or scutellarein. According to the medicine composition, the treatment dosage of inorganic arsenic compounds can be reduced, the cancer inhibition effect can be enhanced, and the systematic toxin of inorganic arsenic compounds can be effectively reduced.

The invention discloses a pharmaceutical composition containing an inorganic arsenic compound and application of the pharmaceutical composition. The pharmaceutical composition contains the inorganic arsenic compound and Niclosamide and is used for preparing a cancer treatment medicine. Niclosamide has the molecular formula of C13H8Cl2N2O4 and the CAS number of 50-65-7. The pharmaceutical composition has a stronger cancer cell killing function than that of independent use of the inorganic arsenic compound or Niclosamide. The therapeutic dose of the inorganic arsenic compound is reduced, the cancer inhibition effect is enhanced, and the systematic poisonousness of the inorganic arsenic compound is effectively reduced.

The invention belongs to the field of biological medicines, and relates to a mutant protein vaccine aiming at tumor necrosis factor alpha (TNF-alpha) and applications of the mutant protein vaccine. The invention aims at providing the protein vaccine which is good in property and takes TNF-alpha as the target spot. According to the scheme, by immunizing the TNF-alpha mutant protein vaccine, the biological activity of the TNF-alpha mutant protein vaccine is inhibited, the cross immunologic reaction is generated in vivo, the biological functions of TNF-alpha are neutralized, and the autoimmune diseases and inflammatory diseases are inhibited. The protein vaccine aiming at TNF-alpha can be used for treating the autoimmune diseases and the inflammatory diseases and preventing the relapse of the autoimmune diseases and the inflammatory diseases.

The invention relates to a nano-drug carrier, which comprises a polyethyleneimine derivative, wherein the fatty acid modification degree of the polyethyleneimine derivative is 0.1-12%, and the biological molecular weight range of the polyethyleneimine derivative is 0-25kDa. The invention also discloses a nano-drug preparation prepared from the nano-drug carrier, a preparation method and application. The nano-drug carrier provided by the invention has the advantages of high drug loading capacity, high encapsulation efficiency, good biocompatibility and the like, is safe and nontoxic, is free from immunogenicity and is biodegradable, a drug treatment dosage is greatly reduced, in addition, the nano-drug carrier can slowly release drugs on a targeting position so as to perform a curative effect for a long time, drug administration frequencies are greatly reduced, and therefore, a toxic and side effect of the drug is further lowered.

The present invention relates to a mRNA comprising a nucleic acid sequence encoding a protein and a signal peptide and a transcription unit, an expression vector or a gene therapy vector comprising a nucleic acid encoding the protein and a signal peptide. Also disclosed herein is a therapeutic composition comprising the mRNA, transcription unit, expression vector or gene therapy vector and use of the therapeutic composition in treating a disease or a condition.